pubmed:abstractText |
Five clinically healthy, male volunteers were each given an intravenous dose of 1.19 mg of 2-methyl-14C-mepindolol sulphate, followed one week later by an oral dose of 20 mg. In addition, the effect of mepindolol sulphate was studied in 3 male test subjects after repeated oral administration for 8 days with a daily dose of 2 x 2.5 mg using the heart rate behaviour model during submaximum ergometer exercise. Synchronously with pharmacodynamics, pharmacokinetic data were also obtained after multiple dosing.
|